Drug

Indication

Discovery

Preclinical

IND-enabling

Phase 1

Phase2

Phase 3

 Immuno-Oncology

Nasopharyngeal carcinoma (NPC) and other cancers

Solid tumors

Solid tumors

A337

Solid tumors

A348

Solid tumors

 Oncology Programs

Colorectal cancer

Solid tumors

Solid tumors

Solid tumors

A315

Gastric cancer

 Cardiovascular Disease

A157

Thrombocytopenia

A336

Anti-coagulation

A167

A167 is a monoclonal antibody targeting PD-L1. It is currently being tested in pivotal Phase 2 clinical trials in the US and China. This program is being developed in collaboration with an external partner. 

KL-A293

KL-A293 is a monoclonal antibody targeting TIM-3. It is currently being tested in a Phase 1 clinical trial in China. Preclinical studies showed promising efficacy in lung and colorectal cancer when given as monotherapy and in combination with anti-PD-1 mAbs. Safety studies showed an MTD of 600 mg/kg (single intravenous injection) and NOAEL of 200 mg/kg. Development and commercial rights are available for licensing or partnership. 

KL-A289

KL-A289 is a monoclonal antibody targeting LAG-3. An IND was recently approved by the NMPA in August 2020 to conduct a Phase 1 clinical trial in China. Preclinical studies showed that the drug was well tolerated and demonstrated efficacy as monotherapy and in combination with anti-PD-1 mAbs. Development and commercial rights are available for licensing or partnership. 

A140

A140 is a monoclonal antibody targeting epidermal growth factor receptor (EGFR) and developed as a cetuximab biosimilar. A Phase 3 study is planned to begin in the near future. Development and commercial rights are available for licensing or partnership. 

A166

A166 is an antibody-drug conjugate (ADC) that is composed of anti-HER2 antibody conjugated to a highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Phase 1 clinical trials conducted in the US and China showed that the drug was well tolerated at 4.8 mg/kg. Furthermore, the drug was able to achieve a Disease Control Rate (DCR) of 100% in breast cancer patients. Based on these promising results, a Phase 2 clinical trial is expected to be initiated by the end of 2020. Development and commercial rights are available for licensing or partnership. 

SKB264

SKB264 is a third-generation antibody-drug conjugate (ADC) that is composed of anti-TROP2 antibody conjugated to a highly potent topoisomerase I inhibitor, via site-specific conjugation and highly stable linkers. The Phase 1 clinical trial is currently recruiting patients in both the US and China, open to populations with locally advanced and/or metastatic solid tumors who are refractory to available standard therapies. In preclinical studies, SKB264 demonstrated comparable or superior safety and efficacy when compared to sacituzumab govitecan. Development and commercial rights are available for licensing or partnership.

A168

A168 is a monoclonal antibody targeting VEGFR2 and developed as a ramucirumab biosimilar. It is currently being tested in a Phase 1 clinical trial in China. Development and commercial rights are available for licensing or partnership. 

 
 
 
 
 
 
 

©2020 by KLUS Pharma Inc.